Stock Events

Stock Events

Canton Strategic 

$2.22
37
-$0.13-5.53% Friday 20:00
+$0.05+2.43%Friday 23:59After hours

Statistics

Day High
2.23
Day Low
2.22
52W High
7.25
52W Low
1.75
Volume
7,636
Avg. Volume
-
Mkt Cap
176.89M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

2DecExpected
Q3 2025
Q4 2025
Next
-0.43
-0.43
-0.42
-0.42
Expected EPS
N/A
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-35.92MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow CNTN. It's not an investment recommendation.
iShares Bitcoin Trust Beneficial Interest
2
IBIT

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Moderna
MRNA
Mkt Cap57.94B
Moderna, Inc. is a competitor because it also focuses on mRNA-based therapies, potentially overlapping with Tharimmune's immunotherapy approaches.
BioNTech
BNTX
Mkt Cap29.28B
BioNTech SE operates in the field of mRNA technology for developing vaccines and therapeutics, directly competing with Tharimmune's technology platform.
Novavax
NVAX
Mkt Cap1.47B
Novavax, Inc. competes in the vaccine development space, particularly in the development of vaccines for infectious diseases, which may overlap with Tharimmune's focus areas.
Pfizer
PFE
Mkt Cap159.99B
Pfizer Inc. has a broad portfolio in vaccines and biopharmaceuticals, making it a competitor in various therapeutic areas that Tharimmune may target.
Gilead Sciences
GILD
Mkt Cap181.18B
Gilead Sciences, Inc. is involved in the development of antiviral drugs and other treatments that could compete with Tharimmune's immunotherapeutic approaches.
Regeneron Pharmaceuticals
REGN
Mkt Cap85.87B
Regeneron Pharmaceuticals, Inc. is known for its work in immunology and infectious diseases, areas that Tharimmune may also be exploring.
Astrazeneca
AZN
Mkt Cap257.42B
AstraZeneca PLC has a diverse biopharmaceutical portfolio, including treatments for cancer and other diseases, potentially competing with Tharimmune's research and development.
Johnson & Johnson
JNJ
Mkt Cap651.25B
Johnson & Johnson operates in various healthcare sectors, including pharmaceuticals with a focus on immunology, making it a competitor to Tharimmune.
Merck
MRK
Mkt Cap376.37B
Merck & Co., Inc. has a strong presence in the development of vaccines and cancer therapies, areas that may intersect with Tharimmune's interests.
Sanofi
SNY
Mkt Cap109.86B
Sanofi is involved in the development of vaccines and treatments for immune system diseases, competing with Tharimmune in the immunotherapy space.

About

Canton Strategic Holdings Inc is engaged in activities related to Canton Network, including the use of Canton Coin, to support blockchain-based infrastructure and the digitization of financial market processes. The company operates in two reportable segments: digital asset treasury and clinical stage bio-technology. Its flagship clinical asset, GV104, is being developed for a specific indication for respiratory and/or nervous system depression in military personnel and chemical incident responders. The expanded pipeline includes other indications for GV104 and GV023, an approach to autoimmune diseases as well as an early-stage multispecific biologic platform.
Show more...
CEO
Mark Wendland
Employees
12
Country
United States
ISIN
US4327053090

Listings

MX
MX
CNTN.MX
BOATS
BOATS
THAR.BOATS
XNAS
US
CNTN

0 Comments

Share your thoughts

FAQ

What is Canton Strategic stock price today?▼
The current price of CNTN is $2.22 USD — it has decreased by -5.53% in the past 24 hours. Watch Canton Strategic stock price performance more closely on the chart.
What is Canton Strategic stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Canton Strategic stocks are traded under the ticker CNTN.
What is Canton Strategic market cap?▼
Today Canton Strategic has the market capitalization of 176.89M
When is the next Canton Strategic earnings date?▼
Canton Strategic is going to release the next earnings report on December 02, 2026.
What is Canton Strategic revenue for the last year?▼
Canton Strategic revenue for the last year amounts to 0 USD.
What is Canton Strategic net income for the last year?▼
CNTN net income for the last year is -35.92M USD.
How many employees does Canton Strategic have?▼
As of August 29, 2026, the company has 12 employees.
In which sector is Canton Strategic located?▼
Canton Strategic operates in the Health & Wellness sector.
When did Canton Strategic complete a stock split?▼
The last stock split for Canton Strategic was on May 28, 2024 with a ratio of 1:15.
Where is Canton Strategic headquartered?▼
Canton Strategic is headquartered in NEW YORK, United States.